Wall Street Zen cuts Akebia Therapeutics to strong sell
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Wall Street Zen downgraded Akebia Therapeutics (NASDAQ:AKBA) from "sell" to "strong sell," even as MarketBeat shows an average analyst rating of "Hold" with a $3.50 price target. The biopharmaceutical stock trades near its 12-month low after meeting EPS estimates but missing revenue forecasts. Institutional investors have made significant changes to their holdings.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.